AstraZeneca: FDA Grants ENHERTU Priority Review For Metastatic HER2-Positive Solid Tumors

(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that the Food and Drug Administration has accepted and granted Priority Review to the supplemental Biologics License Application or sBLA for ENHERTU (fam-trastuzumab deruxtecan-nxki) in the US for https://www.nasdaq.com/articles/astrazeneca:-fda-grants-enhertu-priority-review-for-metastatic-her2-positive-solid-tumors